Receptors for immunoglobulin G (FcyR);Receptores para imunoglobulina G (FcγR)

Medicina

Volumn 38, Issue 1, 2005, Pages 82-95

  Marzocchi Machado, Cleni M ^a   Lucisano Valim, Yara M ^a  

^a UNIVERSITY OF SÃO PAULO   (Brazil)

Author keywords

Fc R; IgG; Immunotherapy

Indexed keywords

AUTACOID; FC RECEPTOR; IMMUNOGLOBULIN G;

ANTIBODY DEPENDENT CELLULAR CYTOTOXICITY; ANTIGEN ANTIBODY COMPLEX; BINDING AFFINITY; CELLULAR DISTRIBUTION; CELLULAR IMMUNITY; CONFERENCE PAPER; EFFECTOR CELL; ENDOCYTOSIS; GENETIC POLYMORPHISM; HUMAN; HUMORAL IMMUNITY; IMMUNOTHERAPY; PHAGOCYTOSIS; SIGNAL TRANSDUCTION;

EID: 23944493637     PISSN: 00766046     EISSN: None     Source Type: Journal    
DOI: 10.11606/issn.2176-7262.v38i1p82-95     Document Type: Conference Paper

References (69)

1. Daëron M. Structural bases of FcyR functions. Int Rev Immunol 1997; 16: 1-27.
2. Rascu A, Repp R, Westerdaal NAC, Kalden JR, Van de Winkel JGJ. Clinical relevance of Fcγ receptor polymorphisms. Ann N Y Acad Sci 1997; 815: 282-95.
3. Galon J, Bouchard C, Fridman WH, Sautès C. Ligands and biological activities of soluble Fcγ receptors. Immunol Letters 1995; 44: 175-81.
4. Zhou MJ, Brown EJ. CR3 (Mac-1, alpha M beta 2, CD11b/CD18) and Fc gamma RIII cooperate in generation of a neutrophil respiratory burst: requirement for Fc gamma RIII and tyrosine phosphorylation. J Cell Biol 1994; 125: 1407-16.
5. Kimberly RP, Salmon JE, Edberg JC. Receptors for immunoglobulin G. Molecular diversity and implications for disease. Arthritis Rheum 1995; 38: 306-14.
6. Deo YM, Graziano RF, Repp R, Van de Winkel JG. Clinical significance of IgG Fc receptors and FcγR-directed immunotherapies. Immunol Today 1997; 18: 127-35.
7. Gessner JE, Heiken H, Tamm A, Schmidt RE. The IgG Fc receptor family. Ann Hematol 1998; 76: 231-48.
8. Daëron M. Fc receptor biology. Annu Rev Immunol 1997; 15: 203-34.
9. Flesch BK, Neppert J. Functions of the Fc receptors for immunoglobulin G. J Clin Lab Anal 2000; 14: 141-56.
10. Miller KL, Duchemin A-M, Anderson CL A novel role for the Fc receptor g subunit: enhancement of Fcγ ligand affinity. J Exp Med 1996; 183: 2227-33.
11. Lanier LL, Yu G, Phillips JP. Co-association of CD3ζ with a receptor (CD16) for IgG Fc on human NK cells. Nature 1989; 42: 803-5.
12. Masuda M, Ross D. Association of all three types of Fc gamma R (CD64, CD32, and CD16) with a gamma-chain homodimer in cultured human monocytes. J Immunol 1993; 51: 7188-95.
13. Orloff DG, Ra CS, Frank SJ, Klausner RD, Kinet JP. Family of disulphide-linked dimers containing the zeta and eta chains of the T-cell receptor and the gamma chain of Fc receptors. Nature 1990; 347: 189-91.
14. Mostov KE, Altschuler Y, Chapin SJ, Enrich C, Low S-H, Luton F, Richman-Eisenstat J, Singer KL, Tang K, Weimbs T. Regulation of protein traffic in polarized epithelial cells: the polymeric immunoglobulin receptor model. Cold Spring Harbor Symp Quant Biol 1997; 60: 775-81.
15. Letourneur O, Kennedy IC, Brini AT, Ortaldo JR, O'Shea JJ, Kinet JP. Characterization of the family of dimers associated with FC receptors (Fcγ RI and Fcγ RIII). J Immunol 1991; 147: 2652-6.
16. Brooks DG, Qiu WQ, Luster A, Ravetch JV. Structure and expression of human IgG FcRII (CD32). Functional heterogeneity is encoded by the alternatively spliced products of multiple genes. J Exp Med 1989; 170: 1369-85.
17. Warmerdam PA, Van de Winkel JG, Vlug A, Westerdaal NA, Capel PJ. A single amino acid in the second Ig-like domain of the human Fcγ receptor II is critical for human IgG2 binding. J Immunol 1991; 147: 1338-43.
18. Van Den Herik-Oudijk IE, Capel PJ, Van Der Bruggen T, Van de Winkel JG. Identification of signalling motifs within human FcγRIIA and FcγRIIB isoforms. Blood 1995; 85: 2202-11.
19. Selvaraj P, Rosse WF, Silber R, Springer TA. The major Fc receptor in blood has a phosphatidylinositol anchor and is deficient in paroxysmal nocturnal haemoglobinuria. Nature 1988; 333: 565-7.
20. Salmon JE, Edberg JC, Kimberly RP. FcγRIII on human neutrophils. Allelic variants have functionally distinct capacities. J Clin Invest 1990; 85: 1287-95.
21. Bux J, Stein E-L, Bierling P, Fromont P, Clay M, Stroncek D, Santoso S. Characterization of a new alloantigen (SH) on the human neutrophil Fcγ receptor III b. Blood 1997; 89: 1027-34.
22. Koene HR, Kleijer M, Roos D, De Haas M, Von Dem Borne AE. FcγRIIIB gene duplication: evidence for presence and expression of three distinct FcgRIIIB genes in NA (1+, 2+) SH(+) individuals. Blood 1998; 91: 673-9.
23. Unkless JC, Shen Z, Lin CW, Debeus E. Function of human FcγRIIA and FcγRIIIB. Semin Immunol 1995; 7: 37-44.
24. Hundt M, Schmidt RE. The glycosylphosphatidylinositol-linked Fc gamma receptor III represents the dominant receptor structure for immune complex activation of neutrophils. Eur J Immunol 1992; 22: 811-6.
25. Simister NE, Rees AR. Isolation and characterization of an Fc receptor from neonatal rat small intestine. Eur J Immunol 1985; 15: 733-8.
26. Junghans RP, Anderson CL. The protection receptor for IgG catabolism is the β2-microglobulin-containing neonatal intestinal transport receptor. Proc Natl Acad Sci USA 1996; 93: 5512-6.
27. Ghetie V, Ward ES. FcRn: the MHC class I-related receptor that is more than an IgG transporter. Immunol Today 1997; 18: 592-8.
28. Raghavan M, Bjorkman PJ. Fc receptors and their interaction with immunoglobulins. Annu Rev Cell Dev Biol 1996; 12: 181-220.
29. Teillaud JL, Bouchard C, Astier A, Teillaud C, Tartour E, Michon J, Galinha A, Moncuit J, Mazieres N, Spagnoli R, Fridman WH, Sautes C. Natural and recombinant soluble low-affinity Fc gamma R: detection, purification, and functional activities, Immunomethods 1994; 4: 48-64.
30. Moldovan I, Galon J, Maridonneau-Parini I, Roman Roman S, Mathiot C, Fridman WH, Sautès-Fridman C. Regulation of production of soluble Fc gamma receptors type III in normal and pathological conditions. Immunol Lett 1999; 68: 125-34.
31. Khayat D, Soubrane C, Andrieu JM, Visonneau S, Erne D, Tourani JM, Beldjord K, Weil M, Fernandez E, Jacquillat C. Changes of soluble CD16 levels in serum of HIV-infected patients: correlation with clinical and biologic prognostic factors. J Infect Dis 1990; 161: 430-5.
32. Middelhoven PJ, Van Buul JD, Hordijk PL, Roos D. Different proteolytic mechanisms involved in Fc gamma RIIIb shedding from human neutrophils. Clin Exp Immunol 2001; 125: 169-75.
33. Reth MG. Antigen receptor tail clue. Nature 1989; 338: 383-4.
34. Gambier JC. New nomenclature for the Reth motif (or ARH1/TAM/ARAM/YXXL) Immunol Today 1995; 16: 110.
35. Durden DL, Kim HM, Galore B, Liu Y. The Fc gamma RI receptor signals through the activation of hck and MAP kinase. J Immunol 1995; 154: 4039-47.
36. Thelen M, Dewald B, Baggiolini M. Neutrophil signal transduction and activation of the respiratory burst. Physiol Rev 1993; 73: 797-821.
37. Aramburu J, Azzoni L, Rao A, Perussia B. Activation and expression of the nuclear factors of activated T cells, NFATp and NFATc, in human natural killer cells: regulation upon CD16 ligand binding. J Exp Med 1995; 182: 801-10.
38. Tsitsikov EM, Fuleihan R, Mcintosh K, Scholl PR, Geha RS. Cross-linking of Fc gamma receptors activates HIV-1 long terminal repeat-driven transcription in human monocytes. Int Immunol 1995; 7: 1665-70.
39. Rao A, Luo C, Hogan PG. Transcription factors of the NFAT family: regulation and function. Annu Rev Immunol 1997; 15: 707-47.
40. Vivier E, Daron M. Immunoreceptor tyrosine-based inhibition motifs. Immunol Today 1997; 18: 286-91.
41. Miettinen HM, Matter K, Hunziker W, Rose JK, Mellman I. Fc receptor endocytosis is controlled by a cytoplasmic domain determinant that actively prevents coated pit localization. J Cell Biol 1992; 116: 875-88.
42. Sinclair NRS, Chan PL. Regulation of the immune response. IV. The role of the Fc-fragment in feedback inhibition by antibody. Adv Exp Med Biol 1971; 12: 609-15.
43. Daëron M, Latour S, Malbec O, Espinosa E, Pina P, Pasmans S, Fridman WH. The same tyrosine-based inhibition motif, in the intracytoplasmic domain of FcγRIIB, regulates negatively BCR-, TCR-, and FcR-dependent cell activation. Immunity 1995; 3: 635-46.
44. Brunkhorst BA, Strohmeier G, Lazzari K, Weil G, Melnick D, Fleit HB, Simons ER. Differential roles of FcγRII and FcγRIII in immune complex stimulation of human neutrophils. J Biol Chem 1992; 267: 20659-66.
45. Blumberg RS, Koss T, Story CM, Barisani D, Polischuk J, Lipin A, Pablo L, Green R, Simister NE. A major histocompatibility complex class I-related Fc receptor for IgG on rat hepatocytes. J Clin Invest 1995; 95: 2397-402.
46. Simister NE, Story CM, Chen HL, Hunt JS. An IgG-transporting Fc receptor expressed in the syncytiotrophoblast of human placenta. Eur J Immunol 1996; 26: 1527-31.
47. Ceuppens JL, Baroja ML, Van Vaeck F, Anderson CL. Defect in the membrane expression of high affinity 72-kD Fcγ receptors on phagocytic cells in four healthy subjects. J Clin Invest 1988; 82: 571-8.
48. Warmerdam PA, Van de Winkel JG, Gosselin EJ, Capel PJ. Molecular basis for a polymorphism of human Fcγ receptor II (CD32). J Exp Med 1990; 172: 19-25.
49. Sanders LA, Feldman RG, Voorhorst-Ogink MM, De Haas M, Rijkers GT, Capel PJ, Zegers BJ, Van de Winkel JG. Human immunoglobulin G (IgG) Fc receptor HA (CD32) polymorphism and IgG2-mediated bacterial phagocytosis by neutrophils. Infect Immun 1995; 63: 73-81.
50. Bredius RG, Derkx BH, Fijen CA, De Wit TP, De Haas M, Weening RS, Van de Winkel JG, Out TA. Fc gamma receptor IIa (CD32) polymorphism in fulminant meningococcal septic shock in children. J Infect Dis 1994; 170: 848-53.
51. Ohto H, Matsuo Y. Neutrophil-specific antigens and gene frequencies in Japanese. Transfusion 1989; 29: 654.
52. Marzocchi-Machado CM, Lucisano-Valim YM. Clearance de imunocomplexos: papel do complemento e dos polimorfonucleares neutrófilos. Medicina (Ribeirã;o Preto) 1997; 30: 234-42.
53. Hamburger MI, Lawley TJ, Kimberly RP, Plotz PH, Frank MM. A serial study of splenic reticuloendothelial system Fc receptor functional activity in systemic lupus erythematosus. Arthritis Rheum 1982; 25: 48-54.
54. Kimberly RP, Parris TM, Inman RD, McDougal JS. Dynamics of mononuclear phagocyte system Fc receptor function in systemic lupus erythematosus. Relation to disease activity and circulating immune complexes. Clin Exp Immunol 1983; 51: 261-8.
55. Marzocchi-Machado CM, Alves CMOS, Azzolini AECS, Polizello ACM, Carvalho IF, Lucisano-Valim YM. Fcgamma and complement receptors: expression, role and co-operation in mediating the oxidative burst and degranulation of neutrophils of Brazilian systemic lupus erythematosus patients. Lupus 2002; 11: 240-8.
56. Duits AJ, Bootsma H, Derksen RH, Spronk PE, Kater L, Kallenberg CG, Capel PJ, Westerdaal NA, Spierenburg GT, Gmelig-Meyling FH, Van de Winkel JGJ. Skewed distribution of IgG Fc receptor IIa (CD32) polymorphism is associated with renal disease in systemic lupus erythematosus patients. Arthritis Rheum 1995; 38: 1832-6.
57. Brandt JT, Isenhart CE, Osborne JM, Ahmed A, Anderson CL. On the role of platelet Fc gamma RIIa phenotype in heparin-induced thrombocytopenia. Thromb Haemost 1995; 74: 1564-72.
58. Van Den Herik-Oudijk IE, Westerdaal NA, Henriquez NV, Capel PJ, Van de Winkel JG. Functional analysis of human Fc gamma RII (CD32) isoforms expressed in B lymphocytes. J Immunol 1994; 152: 574-85.
59. De Haas M, Koene HR, Kleijer M, De Vries E, Simsek S, Van Tol MJ, Roos D, Von Dem Borne AE. A triallelic Fc gamma receptor type IIIA polymorphism influences the binding of human IgG by NK cell Fc gamma RIIIa. J Immunol 1996; 156: 3948-55.
60. Ravetch JV, Perussia B. Alternative membrane forms of Fc gamma RIII (CD16) on human natural killer cells and neutrophils. Cell type-specific expression of two genes that differ in single nucleotide substitutions. J Exp Med 1989; 170: 481-97.
61. Vance BA, Huizinga TW, Wardwell K, Guyre PM. Binding of monomeric human IgG defines an expression polymorphism of FcγRIII on large granular lymphocyte/natural killer cells. J Immunol 1993; 151: 6429-39.
62. Huizinga TW, Kuijpers RW, Kleijer M, Schulpen TW, Cuypers HT, Roos D, Von Dem Borne AE. Maternal genomic neutrophil FcRIII deficiency leading to neonatal isoimmune neutropenia. Blood 1990; 76: 1927-32.
63. Fijen CA, Bredius RG, Kuijper EJ. Polymorphism of IgG Fc receptors in meningococcal disease. Ann Intern Med 1993; 119: 636.
64. Rouard H, Tamasdan S, Moncuit J, Moutel S, Michon J, Fridman WH, Teillaud JL. Fc receptors as targets for immunotherapy. Int Rev Immunol 1997; 16: 147-85.
65. Fanger MW, Erbe DV. Fcg receptors in cancer and infectious disease. Immunol Res 1992; 11: 203-16.
66. Segal DM, Weiner GJ, Weiner LM. Bispecific antibodies in cancer therapy. Curr Opin Immunol 1999; 11: 558-62.
67. Weiner LM, Clark JI, Davey M, Li WS, Garcia de Palazzo I, Ring DB, Alpaugh RK. Phase I trial of 2B1, a bispecific monoclonal antibody targeting c-erbB-2 and Fc gamma RIII. Cancer Res 1995; 55: 4586-93.
68. Repp R, Valerius T, Wieland G, Becker W, Steininger H, Deo Y, Helm G, Gramatzki M, Van de Winkel JG, Lang N. G-CSF-stimulated PMN in immunotherapy of breast cancer with a bispecifc antibody to Fc gamma RI and to HER-2/neu (MDX-210). J Hematother 1995; 4: 415-21.
69. Connor RI, Dinces NB, Howell AL, Romet-Lemonne JL, Pasquali JL, Fanger MW. Fc receptors for IgG (Fc gamma Rs) on human monocytes and macrophages are not infectivity receptors for human immunodeficiency virus type 1 (HIV-1): studies using bispecific antibodies to target HIV-1 to various myeloid cell surface molecules, including the Fc gamma R. Proc Natl Acad Sci U S A 1991; 88: 9593-7.